Novartis on Monday said it had agreed to pay $310 million upfront, with the possibility for more later, for some assets of Boston-based inflammation specialist IFM Therapeutics as the Swiss drugmaker seeks to expand its immunology pipeline.
from Reuters: Business News https://ift.tt/2HR4ibc
Monday, April 1, 2019
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment